Comparative Pharmacology
Head-to-head clinical analysis: OBESTIN 30 versus SANOREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OBESTIN 30 versus SANOREX.
OBESTIN-30 vs SANOREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ObesTin-30 is a selective serotonin reuptake inhibitor (SSRI) that blocks serotonin reuptake, increasing serotonin levels in the synaptic cleft, which modulates appetite and mood.
Serotonin 5-HT2C receptor agonist; stimulates pro-opiomelanocortin (POMC) neurons, leading to release of α-melanocyte-stimulating hormone (α-MSH) and activation of melanocortin-4 receptors in the hypothalamus, reducing appetite.
30 mg subcutaneously once daily.
Oral: 1 mg twice daily for 12 weeks; maximum dose: 2 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in patients with normal renal function; half-life may be prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 2-4 hours; context: requires multiple daily dosing to maintain therapeutic effect.
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose; fecal elimination via biliary excretion accounts for approximately 30%, with the remainder as metabolites.
Renal: 90% unchanged; biliary/fecal: 10%
Category C
Category C
Anorexiant
Anorexiant